GlassScriptPhysician profile
David D Stahl
NPI 1255313391
$7,616.53
in general payments reported to CMS, 2019-2025
27 companies · $945 in 2025
The $945 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $811 · 2021: $1,103 · 2022: $1,242 · 2023: $1,214 · 2024: $1,033 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,192.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,039.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $445.20 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $400.60 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $371.69 | 2019-2022 | |
| Lilly USA, LLC | $295.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Paratek Pharmaceuticals, INC. | $249.98 | 2023-2024 | Nuzyra |
| Amgen INC. | $241.65 | 2021-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $206.15 | 2022-2025 | |
| Glaxosmithkline, LLC. | $179.63 | 2019-2025 | Trelegy Ellipta |
| Mannkind Corporation | $124.99 | 2023 | V-Go |
| Biohaven Pharmaceuticals, INC. | $124.40 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $106.75 | 2019-2022 | |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Amarin Pharma, INC. | $94.54 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $91.83 | 2019-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $89.94 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $78.55 | 2019-2025 | |
| Abbott Laboratories | $71.38 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $70.94 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $60.82 | 2023-2024 | Voquezna |
| Esperion Therapeutics, INC. | $47.74 | 2020-2021 | |
| Abbvie INC. | $25.69 | 2022 | |
| Ironwood Pharmaceuticals, INC | $23.85 | 2023 | Linzess |
| Exact Sciences Corporation | $19.84 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $19.19 | 2025 | Dexcom G6 Transmitter |
| Seqirus USA INC | $18.48 | 2025 | Flucelvax, Fluad |
| Mylan Specialty L.P. | $18.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.